Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo

Human Reproduction

Volumn 27, Issue 11, 2012, Pages 3273-3278

  Moll, E ^a   Van Wely, M ^a,b   Lambalk, C B ^a   Bossuyt, P M M ^b   Van Der Veen, F ^a  

^a Center for Reproductive Medicine   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

clomifene; health related quality of life; metformin; polycystic ovary syndrome; randomized clinical trial

Indexed keywords

CLOMIFENE CITRATE; DYDROGESTERONE; METFORMIN; PLACEBO;

ABDOMINAL PAIN; ADULT; APPETITE DISORDER; ARTICLE; CONTROLLED STUDY; DISTRESS SYNDROME; FATIGUE; FEMALE; FLATULENCE; HUMAN; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OVULATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTTERDAM SYMPTOM CHECKLIST; UNSPECIFIED SIDE EFFECT;

EID: 84867760552     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des310     Document Type: Article

References (33)

1. Barbieri RL. H yperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. Jreprod Med 1994;39:327-336.
2. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2011;26:2442-2451.
3. Boivin J, Takefman J, Braverman A. The fertility quality of life (FertiQoL) tool: development and general psychometric properties. Hum Reprod 2011;26:2084-2091.
4. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998;83:1976-1987.
5. De Haes JC, Olschewski M, Fayers P, Visser MR, Cull A, Hopwood P, Sanderman R. Measuring the Quality of Life of Cancer Patients with the Rotterdam Symptom Checklist (RSCL): a Manual. The Netherlands: Northern Center for Health R esearch, University of G roningen, G roningen, 1996.
6. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol 2011;117:145-152.
7. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2012;97:225-230.
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin r esistance, independent of o besity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
10. Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003;18:2357-2362.
11. ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
12. Fielding S, Fayers PM, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. Health Qual Life Outcomes 2009;7:57.
13. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-b lind, placebo-Controlled, dose-response trial. Am J Med 1997;103:491-497.
14. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary s yndrome, a self-administered q uestionnaire, was validated. J Clin Epidemiol 2004;57:1279-1287.
15. Harris-Glocker M, Davidson K, Kochman L, Guzick D, Hoeger K. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral c ontraceptives, with or without metformin. Fertil Steril 2010;93:1016-1019.
16. Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 2002;17:2495-2499.
17. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002;77:91-97.
18. Jedel E, Waern M, Gustafson D, Landen M, Eriksson E, Holm G, Nilsson L, Lind AK, Janson PO, Stener-Victorin E. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod 2010;25:450-456.
19. Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, Mulgrew NC, Shepherd KE, Wilkinson VH, Singh M et al. The polycystic ovary syndrome health-related quality of life questionnaire (PCOSQ): a validation. Hum Reprod 2004;19:371-377.
20. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Williams NI, Coney P, Legro RS. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011;95:1059-1066.
21. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA et al. C lomiphene, m etformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-566.
22. Li Y, Li Y, Yu Ng EH, Stener-Victorin E, Hou L, Wu T, Han F, Wu X. Polycystic ovary syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from a meta-analysis. Fertil Steril 2011;96:452-458.
23. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (m etformin, t roglitazone, r osiglitazone, p ioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; CD003053.
24. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. Br Med J 2006; 332:1485.
25. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007; 13:527-537.
26. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15:477-488.
27. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose t olerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-363.
28. Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod 1997;12(Suppl 1):53-62.
29. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.
30. O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76:1241-1247.
31. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (m etformin, rosiglitazone, p ioglitazone, D-chiro-inositol) for women with polycystic ovary s yndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053.
32. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces h yperinsulinemia, insulin r esistance, h yperandrogenemia, and systolic blood Pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43:647-654.
33. Zwinderman AH. Statistical analysis of longitudinal quality of life data with missing measurements. Qual Life Res 1992;1:219-224.